Catégorie : Cannabis et législation

Marijuana and acute health care contacts in Colorado, George SamWang et al., 2017

Marijuana and acute health care contacts in Colorado George SamWang, Katelyn Hall, Daniel Vigil, Shireen Banerji, AndrewMonte, Mike VanDyke Preventive Medicine, 2017, 104, 24-30. doi: 10.1016/j.ypmed.2017.03.022   a b s t r a c t Over 22 million Americans are current users of marijuana; half of US states allow medical marijuana, and several allow recreational marijuana. The objective of this study was to evaluate the impact marijuana has on hospitalizations, emergency department (ED) visits, and regional poison center (RPC) calls in Colorado, a medical and recreational marijuana state. This is a retrospective review using Colorado Hospital Association hospitalizations and ED visits with marijuana-related billing codes, and [...]

Lire la suite

What Are the Benefits of CBD ?, New York Times, 16 octobre 2019

What Are the Benefits of CBD ? More than 60 percent of CBD users were taking it for anxiety, according to a survey of 5,000 people. Does it help? THE NEW YORK TIMES,   By Dawn MacKeen Published Oct. 16, 2019 https://www.nytimes.com/2019/10/16/style/self-care/cbd-oil-benefits.html Credit...Photo Illustration by The New York Times; Shutterstock The CBD industry is flourishing, conservatively projected to hit $16 billion in the United States by 2025. Already, the plant extract is being added to cheeseburgers, toothpicks and breath sprays. More than 60 percent of CBD users have taken it for anxiety, according to a survey of 5,000 people, conducted by the Brightfield Group, a cannabis market [...]

Lire la suite

FDA, FTC warn company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD, Parkinson’s and Alzheimer’s disease, 2019

FDA, FTC warn company marketing unapproved cannabidiol products with unsubstantiated claims to treat teething and ear pain in infants, autism, ADHD, Parkinson’s and Alzheimer’s disease FDA is also working quickly to evaluate regulatory policies related to cannabis and cannabis-derived ingredients like CBD October 22, 2019 https://www.fda.gov/news-events/press-announcements/fda-ftc-warn-company-marketing-unapproved-cannabidiol-products-unsubstantiated-claims-treat-teething     Today, the U.S. Food and Drug Administration and the Federal Trade Commission posted a joint warning letter to Rooted Apothecary LLC, of Naples, Florida, for illegally selling unapproved products containing cannabidiol (CBD) online with unsubstantiated claims that the products treat teething pain and ear aches in infants, autism, attention-deficit/hyperactivity disorder (ADHD), as well as Parkinson’s and Alzheimer’s disease, [...]

Lire la suite

Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users, 2014

Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users M.O. Bonn-Miller, M.T. Boden, M.M. Bucossi, K.A. Babson The American Journal of Drug and Alcohol Abuse, 2014, 40, (1), 23-30. doi : 10.3109/00952990.2013.821477.   OBJECTIVES Little research has investigated the demographic and symptom profile of medical cannabis users in states in the USA that have legalized cannabis use. METHODS In the present cross-sectional study, we investigated the demographic profile of 217 adults currently receiving medical cannabis, as well as differences in problematic use and perceived helpfulness in terms of (i) symptoms of psychological disorders and pain, and (ii) motives for use. RESULTS Findings indicated that medical cannabis users (i) [...]

Lire la suite

US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws 1991-1992 to 2012-2013, Deborah S. Hasin et al., 2017

US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws 1991-1992 to 2012-2013 Deborah S. Hasin, Aaron L. Sarvet, Magdalena Cerda, Katherine M. Keyes, Malka Stohl, Sandro Galea, Melanie M. Wall JAMA Psychiatry, 2017, 74, (6), 579–610. Doi : 10.1001/jamapsychiatry.2017.0724 PMCID: PMC5539836      PMID: 28445557 Key Points Question Are US state medical marijuana laws one of the underlying factors for increases in risk for adult cannabis use and cannabis use disorders seen since the early 1990s? Findings In this analysis using US national survey data collected in 1991-1992, 2001-2002, and 2012-2013 from 118 497 participants, the risk for cannabis use and cannabis use disorders increased at a significantly [...]

Lire la suite

The effect of cannabis laws on opioid use, J.L. Flexon et al., 2019

The effect of cannabis laws on opioid use. J.L. Flexon, L. Stolzenberg, S.J. d'Alessio International Journal of Drug Policy, 2019, 74, 152-159. doi : 10.1016/j.drugpo.2019.09.013. Abstract BACKGROUND : Many Americans rely on opioids at varying dosages to help ameliorate their suffering. However, empirical evidence is mounting that opioids are ineffective at controlling non-cancer related chronic pain, and many argue the strategies meant to relieve patient suffering are contributing to the growing opioid epidemic. Concurrently, several states now allow the use of medical cannabis to treat a variety of medical conditions, including chronic pain. Needing more exploration is the impact of cannabis laws on general opioid reliance [...]

Lire la suite

Histoire. La résine de cannabis : remède miracle ou poison d’Orient ?, Le Courrier International, David A Guba Jr.,2019.

Planche botanique de Cannabis sativa tirée du Nordisk familjebok, une encyclopédie suédoise publiée entre 1876 et 1957. Wikicommons Histoire. La résine de cannabis : remède miracle ou poison d’Orient ? David A Guba Jr.11 octobre 2019   XIXe siècle – France. Dans les années 1830, alors que la pandémie de choléra frappe l’Europe, le milieu médical français se passionne pour la résine de cannabis, parée de toutes les vertus. Nombreux sont ceux qui ont applaudi à l’annonce d’un début de réglementation prenant mieux en compte les enjeux de santé publique sur la consommation de cannabis en France. L’Agence nationale de sécurité du médicament a salué les [...]

Lire la suite

Du cannabis dans le PLFSS, Benoît Thelliez, 2019

Du cannabis dans le PLFSS Le député Olivier Véran (LREM, Isère) va défendre un amendement introduisant une expérimentation du cannabis thérapeutique. © FOTOLIA_FABIOBERTI.IT Les choses se pré­cisent. Après que l'Agence na­tio­nale de sé­cu­rité du mé­di­ca­ment et des pro­duits de santé (ANSM) a sous­crit, dé­but juillet 2019, aux pro­po­si­tions du co­mité scien­ti­fique spé­cia­lisé tem­po­raire sur le cadre pra­tique de l’ac­cès au can­na­bis à vi­sée thé­ra­peu­tique en vue d’une ex­pé­ri­men­ta­tion en France, c'est dé­sor­mais le cadre lé­gal qui va être dis­cuté à l'As­sem­blée na­tio­nale. In­vité à l'an­tenne de RTL, le neu­ro­logue et dé­puté de la ma­jo­rité, Oli­vier Vé­ran, a ainsi ex­pli­qué qu'il al­lait pré­sen­ter et dé­fendre un amen­de­ment au pro­jet de loi de fi­nan­ce­ment de la sé­cu­rité so­ciale (PLFSS) pour 2020 vi­sant à mettre en place, au plus vite, une ex­pé­ri­men­ta­tion en mi­lieu hos­pi­ta­lier. Se­lon ses dires, elle de­vrait concer­ner « en­vi­ron 3 000 ma­lades » qui se­ront « sui­vis par des [...]

Lire la suite

Marché du cannabis thérapeutique en France : les grands acteurs étrangers dans les starting-blocks, RESPADD, Actualités des Addictions n°102, septembre 2019

Marché du cannabis thérapeutique en France : les grands acteurs étrangers dans les starting-blocks RESPADD,  Actualités des Addictions n°102, septembre 2019 https://www.respadd.org/publications/veille-bibliographique/     L'expérimentation du cannabis thérapeutique en France, qui doit débuter d'ici la fin de l'année, attire de grands acteurs étrangers spécialisés qui tentent de se positionner au plus tôt sur ce marché pouvant concerner jusqu'à 2,3 millions de patients, selon le Syndicat professionnel du chanvre (SPC) français. Le lancement de cette expérimentation a été entériné en juillet par l'Agence nationale de sécurité du médicament et des produits de santé (ANSM), sur la base d'un avis rendu par un comité scientifique spécialisé temporaire (CSST) [...]

Lire la suite

Priority Considerations for Medicinal Cannabis-Related Research, Marcel O. Bonn-Miller et al., 2019

Priority Considerations for Medicinal Cannabis-Related Research Marcel O. Bonn-Miller, Charles V. Pollack, Jr., David Casarett, Richard Dart, Mahmoud ElSohly, Larry Good, Manuel Guzman, Lumır Hanus, Kevin P. Hill, Marilyn A. Huestis, Eric Marsh, Susan Sisley, Nancy Skinner, Judith Spahr, Ryan Vandrey, Eugene Viscusi, Mark A. Ware, and Donald Abrams Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, 1-19. DOI: 10.1089/can.2019.0045   Keywords : medicinal cannabis; medical marijuana   Introduction and Rationale The National Academy of Sciences, Engineering, and Medicine’s 2017 publication The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research provided a significant contribution by synthesizing the existing evidence base [...]

Lire la suite